perampanel

Perampanel is a first-in-class, highly selective, non-competitive antagonist of the AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptor, developed by Eisai. It is used as an antiepileptic drug for the treatment of partial-onset seizures (with or without secondary generalization) and primary generalized tonic-clonic seizures in patients aged 12 years and older, with some regions approving use in children as young as 4 years. Perampanel works by inhibiting glutamate-mediated excitatory neurotransmission at postsynaptic AMPA receptors, thereby reducing neuronal hyperexcitability associated with epileptic seizures. It can be used both as adjunctive therapy and monotherapy for epilepsy. The drug carries a black box warning due to risks of serious psychiatric and behavioral changes including aggression, homicidal ideation, and suicidal thoughts. Other adverse effects include dizziness, somnolence, ataxia, blurred vision, irritability, speech disturbance; it may reduce the efficacy of levonorgestrel-containing oral contraceptives by about 40%. Perampanel is classified as a controlled substance due to its potential for abuse[1][3][5][6].

Brand names

Fycompa卫克泰

Other names

吡仑帕奈